Cytokinetics, Inc.

Amgen Inc.

Astellas Pharma Gmbh

Darren Hwee

Adam Kennedy

Jeffrey R. Jasper

Fady Malik

Bradley Paul Morgan

David John Morgans, Jr

Xiangping Qian

Roman Sakowicz

Erica Anne Kraynack

Pu-Ping Lu

Jeffrey T Finer

James Hartman

Alexander Ramon Muci

Kathleen Ann Elias

Whitney Walter Smith

Adam Lewis Tomasi

Hiroaki Tanaka

Luke W Ashcraft

Takashi Kamikubo

Scott E Collibee

Masanori Miura

Jeffrey Warrington

Tomoyuki Saito

Kenneth Wood

Susumu Yamaki

Christopher Bentley Shumate

Ippei Sato

Yuji Matsushima

Yasuhiro Shiina

Marc Andrew Garard

Kayoko Mihara

Hiroshi Kiyohara

Narimon Honarpour

Munemichi Ohe

Bainian Feng

Alan James Russell

Christophe Beraud

Richard Freedman

Alex R Muci

Todd Tochimoto

Andrew Craven

Malar Pannirselvam

Aaron Hinken

David J Morgans

Andrew A Wolff

Richard Hansen

Lixin Meng

Jesse Cedarbaum

John Mao

Jim Hartman

Stuart Kupfer

Stephen B Heitner

Laura Ann Robertson

Qi Wohltman

Anna Osmukhina

Todd c/o Cytokynetics Inc Tochimoto

Alex c/o Cytokinetics Inc Muci

Jeffrey R Jasper

Jeremy M Shefner

Jinsy A Andrews

Jeffrey Michael Warrington

Scott Emile Collibee

Methods for treating obstructive hypertrophic cardiomyopathy are described herein. The treatment methods include the administration of a cardiac myosin inhibitor (CK-3773274, also referred to as CK-274 or aficamten) and may include titrating an administrated daily dose based on one or more components of an echocardiogram. The daily dose may be increased, maintained, decreased, or terminated, based on the echocardiogram.

Methods for treating hypertrophic cardiomyopathy

Provided herein are methods of treating a subject with heart failure, comprising administering to the subject an initial dose of a cardiac sarcomere activator (CSA) for an initial time period, and subsequently administering to the subject a dose of the CSA based on the subject's plasma concentration of the CSA at the end of the initial time period.

Methods of treating heart failure with cardiac sarcomere activators

Provided herein are methods of treating heart failure in patients exhibiting one or more additional features, comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil, or a hydrate, salt, or salt of a hydrate thereof.

Methods of treating heart failure by administering omecamtiv mecarbil

Methods for treating heart failure are described herein. Treatment methods include administering a cardiac sarcomere activator (e.g., omecamtiv mecarbil, or a pharmaceutically acceptable salt and/or hydrate thereof) to a subject in need thereof. Treatment methods also include adjusting a dose level of the CSA, for example, to increase, decrease, or maintain a dose level, based on the subject's plasma concentration of the CSA determined after administration of the first dose level of the CSA has started. Provided herein are also treatment methods effective to achieve a target concentration range of the CSA and dose in a single step following a single plasma concentration determination.

Methods for treating heart failure by administering cardiac sarcomere activators

Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.

Tetrahydroisoquinoline derivatives

Provided is a method for treating ALS in a subject, comprising administering to the subject a therapeutically effective amount of riluzole and a therapeutically effective amount of CK-2017357. Also provided are methods of reducing the variability of riluzole exposure (e.g., Cand/or AUC) in a subject, methods of reducing the variability of riluzole exposure (e.g., Cand/or AUC) between two or more subjects, methods of decreasing the total daily dose of riluzole in a subject, methods of increasing the half-life of riluzole in a subject, methods for decreasing the frequency of riluzole dosing in the subject, and methods for reducing the incidence and/or severity of adverse events in a subject treated with riluzole.

Combination ALS therapy

Provided are compounds of Formula I and compounds of Formula II: and pharmaceutically acceptable salts thereof, and methods for their use.

Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use

Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

Heterocyclic sulfonamides

Provided are methods for treating myasthenia gravis in a patient, comprising administering to the patient an effective amount of at least one chemical entity chosen from compounds of Formula I and compounds of Formula II: and pharmaceutically acceptable salts thereof.

Growing community of inventors

Burlingame, CA, United States of America

Fady Malik